These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 36263117)

  • 1. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS.
    Tang S; Wu Z; Xu L; Wen Q; Zhang X
    Front Pharmacol; 2022; 13():970066. PubMed ID: 36263117
    [No Abstract]   [Full Text] [Related]  

  • 2. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.
    Xu H; Xu N; Wang Y; Zou H; Wu S
    Front Pharmacol; 2024; 15():1442002. PubMed ID: 39188956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS.
    Rao J; Chen X; Liu Y; Wang X; Cheng P; Wang Z
    Expert Opin Drug Saf; 2024 Oct; 23(10):1317-1325. PubMed ID: 39021273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
    Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
    Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data.
    Li B; Zhang J; Huang A; Chen Y; Wei Q
    Int J Cardiol; 2024 Oct; 412():132305. PubMed ID: 38944350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.
    Zhu J; Hu M; Liang Y; Zhong M; Chen Z; Wang Z; Yang Y; Luo Z; Zeng W; Li J; Du Y; Liu Y; Yang C
    Heliyon; 2024 Jul; 10(14):e34837. PubMed ID: 39149028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Dec; 52(6):2195-2205. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten.
    Yukselen Z; Raju AKV; Kumar PA; Ujjawal A; Dasari M; Parajuli S; Nakhla M; Bansal K; Ganatra S; Dani SS
    Am J Cardiovasc Drugs; 2024 Nov; 24(6):791-799. PubMed ID: 39164512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
    Nicholls C; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.
    Zhang Y; Jia X; Shi X; Chen Y; Xue M; Shen G; Wen L; Qiao Y; Yang Y
    Gen Hosp Psychiatry; 2024; 90():22-29. PubMed ID: 38901166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data mining of the public version of the FDA Adverse Event Reporting System.
    Sakaeda T; Tamon A; Kadoyama K; Okuno Y
    Int J Med Sci; 2013; 10(7):796-803. PubMed ID: 23794943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
    Sakaeda T; Kadoyama K; Minami K; Okuno Y
    Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of adverse events involving bleeding associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system.
    Fahmy AI; Mekkawy MA; Abou-Ali A
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):175-181. PubMed ID: 30738497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.